

**The Australian Stock Exchange Limited,
Companies Announcements Office
SYDNEY**

Via: asxonline

18th February 2005

BOARD CHANGES FOR AIM ADMISSION

VRI has made the following changes to its board in preparation for admission to the AIM in London:

1. Mr Kim Slatyer has resigned as Executive Chairman and has been appointed CEO. This move is intended to comply with corporate governance recommendations.
2. The Hon Sir Victor Garland KBE has been appointed a non-executive Chairman based in the UK. This move is consistent with standard practice of Australian AIM - listed companies. Sir Victor is highly regarded in the UK capital markets, having served on the boards of some 30 companies including the global fund manager, Prudential.
3. Prof. Ron Penny AO has been appointed a non-executive director. Prof. Penny is an eminent Australian immunologist in both clinical and research areas.
4. Dr Peter French has resigned as a director and will continue to work for the company on innovation and business development initiatives.
5. Mr Bryan Gardiner has been appointed a non-executive director. Mr Gardiner is an Australian lawyer with considerable commercial, corporate and public company experience in Australia and Singapore.

Mr Geoff Wild AM, one of Australia's leading marketing and communications experts, will remain a non-executive director. Mr Wild has significant experience on public company boards.

Mr Kim Slatyer, CEO – 02/9209 4268

VRI BioMedical Ltd
is bringing science to wellness by
commercialising a range of
products for health maintenance and
disease prevention, based on robust
scientific and clinical research.
VRI BioMedical has developed
extensive intellectual property
in three platform technologies:
probiotics diagnostics vaccines

VRI BioMedical Ltd
ACN 084 464 193 - ABN 97 084 464 193
Suite G09, 1 Central Avenue, Australian Technology Park, Eveleigh, Sydney NSW 1430, Australia
Phone: +61 2 9209 4268 Fax: +61 2 9209 4256